{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-000853","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.874379+00:00","generated_at":"2026-06-27T19:15:09.311445+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"EyePoint appoints Michael C. Pine as Chief Corporate Development and Strategy Officer","bullets":["Appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, effective January 10, 2022.","Annual base salary of $420,000; sign-on bonus of $108,000 payable in two equal tranches.","Granted options to purchase 100,000 shares at $12.62/share, vesting 25% on first anniversary then monthly through fourth year.","Mr. Pine brings over 20 years of pharma experience, most recently SVP at Medexus Pharmaceuticals.","Inducement award under Nasdaq Listing Rule 5635(c)(4); subject to forfeiture provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-000853","json":"https://secwatch.observer/filing/0001564590-22-000853.json","markdown":"https://secwatch.observer/filing/0001564590-22-000853.md","text":"https://secwatch.observer/filing/0001564590-22-000853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/0001564590-22-000853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/eypt-8k_20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:15:09.311445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b256ae779","claim":"Michael C. Pine was appointed as Chief Corporate Development and Strategy Officer at EyePoint, Inc..","evidence_excerpt":"On January 10, 2022 (the “ Start Date ”), EyePoint Pharmaceuticals, Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Michael C. Pine, age 46, as the Company’s Chief Corporate Development and Strategy Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/0001564590-22-000853-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Corporate Development and Strategy Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}